Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

Condition:   InfluenzaIntervention:   Biological: VAX161-01C vaccineSponsor:   VaxInnate CorporationCompleted - verified September 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials